Calamos Advisors LLC Lowers Position in Natera, Inc. $NTRA

Calamos Advisors LLC lowered its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 11.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,122 shares of the medical research company’s stock after selling 3,515 shares during the quarter. Calamos Advisors LLC’s holdings in Natera were worth $4,413,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of NTRA. Price T Rowe Associates Inc. MD raised its holdings in shares of Natera by 56.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares during the last quarter. Nuveen LLC bought a new stake in Natera in the 1st quarter worth about $113,375,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Natera by 140.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,253,790 shares of the medical research company’s stock valued at $177,298,000 after buying an additional 732,156 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock worth $1,041,055,000 after buying an additional 660,538 shares in the last quarter. Finally, Ninety One UK Ltd boosted its stake in shares of Natera by 149.1% in the 2nd quarter. Ninety One UK Ltd now owns 562,985 shares of the medical research company’s stock worth $95,111,000 after buying an additional 336,985 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on the company. Piper Sandler increased their price target on Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday. BNP Paribas upgraded Natera to a “hold” rating and set a $172.00 price objective for the company in a research note on Monday, October 27th. BTIG Research lifted their target price on Natera from $210.00 to $230.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $210.00 to $240.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, BNP Paribas Exane upgraded shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 price objective for the company in a report on Monday, October 27th. Fifteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Natera has an average rating of “Moderate Buy” and an average target price of $216.65.

Natera Stock Performance

NTRA stock opened at $200.67 on Friday. The stock has a fifty day moving average of $180.78 and a 200-day moving average of $165.22. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $212.21. The company has a market capitalization of $27.69 billion, a price-to-earnings ratio of -87.63 and a beta of 1.75.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period last year, the company earned ($0.26) earnings per share. Equities analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Insider Buying and Selling at Natera

In related news, insider John Fesko sold 928 shares of Natera stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $191.46, for a total value of $177,674.88. Following the completion of the transaction, the insider directly owned 150,699 shares in the company, valued at approximately $28,852,830.54. The trade was a 0.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $198.60, for a total transaction of $595,800.00. Following the sale, the insider directly owned 112,061 shares in the company, valued at $22,255,314.60. The trade was a 2.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 223,336 shares of company stock valued at $42,990,633. 5.63% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.